Paper Review Records
全部论文审稿周期
5 篇有效样本 · 按发表日期由新到旧排列
审稿天数=录用日期-收稿日期；保留 PDF/DOI/网页源链接
198
天
Endothelial Cells Contribute to the Immune-Vascular Milieu Characterizing VETC+ HCC
作者
Barbara Durante; Simone Zanella; Francesco de Napoli; Beatrice Esposito; Camilla De Carlo; Reha Akpinar; Cristina Richichi; Francesca Lazzaroni; Barbara Franceschini; Cristiana Soldani; Fabio Grizzi; Fabio Pasqualini; Ana Lleo; Guido Torzilli; Fabio Procopio; Luca Viganò; Salvatore Piscuoglio; Charlotte K.Y. Ng; Federica Airi; Elvezia Paraboschi; Ines Simeone; Luca Di Tommaso展开收起
作者单位
1. Pathology Unit, IRCCS Humanitas Research Hospital, Milan, Italy; 2. Department of Biomedical Sciences, Humanitas University, Milan, Italy; 3. Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico, Milan, Italy; 4. Hepatobiliary Immunopathology Lab, Department of Gastroenterology, IRCCS Humanitas Research Hospital, Rozzano, Italy; 5. Department of Immunology and Inflammation, IRCCS Humanitas Research Hospital, Rozzano, Italy; 6. Division of Internal Medicine and Hepatology, Department of Gastroenterology, IRCCS Humanitas Research Hospital, Rozzano, Italy; 7. Division of Hepatobiliary and General Surgery, Department of Surgery, IRCCS Humanitas Research Hospital, Rozzano, Italy; 8. Hepatobiliary Unit, Department of Minimally Invasive General and Oncologic Surgery, Humanitas Gavazzeni University Hospital, Bergamo, Italy; 9. Department of Electrical Engineering and Information Technologies, University of Naples “Federico II”, Naples, Italy展开收起
134
天
Atezolizumab plus Bevacizumab with or without Transarterial Chemoembolization as First-Line Treatment for Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma: A Nationwide Multicenter Retrospective Study
作者
Xiao-Wu Zhang; Li-Wei Deng; Yin-Gen Luo; Yin-Fa Xie; Rui-Bao Liu; Hai-Bo Shao; Tong-Guo Si; Dui-Ping Feng; Jian Wang; Yu Zhang; Qing-Dong Li; Hong-Tao Hu; Wei-Jun Fan; Peng Song; Li-Nan Yin; Yan Wang; Yi Chen; Tian-Shi Lv; Yong Xie; Tian-Yi Hua; Jing Xiao; Rui-Can Nie; Lu-Jun Shen; Zhi-Ming Xuan; Chang Liu; Xue-Gang Yang; Xu Chang; Xiao Li展开收起
作者单位
1. Department of Interventional Therapy, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; 2. Department of Interventional Therapy II, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China; 3. Department of Interventional Radiology, Harbin Medical University Cancer Hospital, Harbin, China; 4. Department of Interventional Radiology, The First Hospital of China Medical University, Liaoning, China; 5. Department of Interventional Treatment, Tianjin Cancer Hospital Airport Hospital, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer , Tianjin, China; 6. Department of Interventional Therapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Tianjin, China; 7. Department of Oncology and Vascular Intervention, First Hospital of Shanxi Medical University, Shanxi Provincial Clinical Research Center for Interventional Medicine, Taiyuan, China; 8. Department of Interventional Radiology and Vascular Surgery, Peking University First Hospital, Beijing, China; 9. Department of Hepatobiliary and Pancreatic Surgery, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China; 10. Vascular and Interventional Department, Chongqing University Cancer Hospital, Chongqing, China; 11. Department of Interventional Radiology, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China; 12. Department of Minimally Invasive Interventional Therapy, Sun Yat-sen University Cancer Center, Guangzhou, China; 13. Department of Interventional Therapy, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital and Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China; 14. Intervention Center, West China Hospital, Sichuan University, Chengdu, China; 15. Department of Interventional Therapy, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, China展开收起
125
天
Baseline Predictors, Prognostic Impact, and Risk Stratification of Early Progressive Disease on Atezolizumab-Bevacizumab in Unresectable Hepatocellular Carcinoma: A Multicenter Real-World Study
作者
Takuya Sho; Goki Suda; Tamami Abe; Masashi Ninomiya; Kei Endo; Yudai Fujiwara; Hiroshi Numao; Go Igarashi; Mio Tsuruoka; Chikara Iino; Kenta Yoshida; Satoshi Sato; Masato Nakai; Masatsugu Ohara; Takashi Kitagataya; Naoki Kawagishi; Tomohiro Katsumi; Keita Maki; Wataru Sato; Shinichiro Minami; Kazumichi Abe; Masashi Fujita; Yoshiya Yamamoto; Masaru Baba; Takashi Meguro; Takayoshi Oikawa; Nobukazu Tanabe; Yoshiyuki Ueno; Naoya Sakamoto; Hidekatsu Kuroda; for NORTH Japan HCC study group展开收起
作者单位
1. Department of Gastroenterology and Hepatology, Graduate School of Medicine, Hokkaido University, Sapporo, Japan; 2. Division of Internal medicine, Department of Gastroenterology and Hepatology, Iwate Medical University, Morioka, Japan; 3. Divison of Gastroenterology, Tohoku University Hospital, Sendai, Japan; 4. Aomori Prefectural Central Hospital, Aomori, Japan; 5. Department of Gastroenterology, Hematology and Clinical immunology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan; 6. Department of Gastroenterology, Yamagata University Faculty of Medicine, Yamagata, Japan; 7. Department of Gastroenterology, Akita University Graduate School of Medicine, Akita, Japan; 8. Department of Gastroenterology, School of Medicine, Fukushima Medical University, Fukushima, Japan; 9. Hakodate City Hospital, Hakodate, Japan; 10. Department of Gastroenterology and Hepatology, Japan Community Health Care Organization (JCHO) Hokkaido Hospital, Sapporo, Japan; 11. Hokkaido Gastroenterology Hospital, Sapporo, Japan; 12. Japanese Red Cross Morioka Hospital, Morioka, Japan; 13. Department of Gastroenterology, NHO Sendai Medical Center, Sendai, Japan展开收起
339
天
Outcomes by Comorbidities with Tremelimumab and Durvalumab in the Randomized, Controlled Phase 3 HIMALAYA Study in Unresectable Hepatocellular Carcinoma
作者
Lorenza Rimassa; Farshid Dayyani; Robin K. Kelley; Bruno Sangro; Stephen L. Chan; Hitomi Nakamura; Lucy Clark; Ioannis Xynos; Ghassan K. Abou-Alfa展开收起
作者单位
1. Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy; 2. Hepatopancreatobiliary Oncology Unit, Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Rozzano, Italy; 3. Department of Medicine, Division of Hematology/Oncology, University of California Irvine, Orange, CA, USA; 4. Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, USA; 5. Liver Unit and HPB Oncology Area, Clínica Universidad de Navarra and CIBEREHD, Pamplona, Spain; 6. State Key Laboratory of Translational Oncology, Department of Clinical Oncology, Sir Yue-Kong Pao Center for Cancer, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, Hong Kong SAR; 7. Global Medical Affairs, AstraZeneca, Cambridge, UK; 8. Oncology R&D, AstraZeneca, Cambridge, UK; 9. Oncology R&D, Late-Stage Development, AstraZeneca, Cambridge, UK; 10. Department of Medicine, Memorial Sloan Kettering Cancer Center, Cornell University, New York, NY, USA; 11. Weill Medical College, Cornell University, New York, NY, USA; 12. Trinity College Dublin, Dublin, Ireland展开收起
189
天
Selective Conventional Transarterial Chemoembolization Using a Glass Membrane Emulsification Device in Hepatocellular Carcinoma: Multicenter Clinical Trial in Japan
作者
Toshihiro Tanaka; Hiroshi Anai; Tetsuya Masada; Satoru Sueyoshi; Takeshi Sato; Shohei Toyoda; Takeshi Matsumoto; Yuto Chanoki; Keisuke Oshima; Sho Shimizu; Mariko Irizato; Ryosuke Taiji; Kiyoyuki Minamiguchi; Hideki Kunichika; Hiroyuki Kurakami; Shigeo Ichihashi; Hideyuki Nishiofuku展开收起
作者单位
1. Diagnostic and Interventional Radiology, Nara Medical University, Kashihara, Japan; 2. Nara City Hospital, Sakurai, Japan; 3. Nara Prefectural General Medical Center, Sakurai, Japan; 4. Saiseikai-Chuwa Hospital, Sakurai, Japan; 5. Institute for Clinical and Translational Science, Nara Medical University, Sakurai, Japan展开收起
Expert Matching · Case Demo
把投稿要求，转成可验证的期刊方案
说清专业、时限和作者背景，CrushSCI 结合真实审稿样本，给出拟题方向、期刊初筛与周期判断。
客户询问
我是环境工程专业，需要一篇 SCI，希望 3 个月内见刊。没有基金，也没有大牛挂名，可以投哪些期刊？
CrushSCI回复
可以。先按 90 天时限做可行性筛选，同步查找无基金、无知名作者挂靠的典型论文案例，作为选刊依据。重点核对研究质量与期刊 scope。
- 拟题建议
- 《融合机器学习与生命周期评价的城市污水处理碳排放预测与优化》
样本口径2026 年最近 5 篇有效论文样本
平均审稿62 天
中位数65 天